Anakinra treatment efficacy in reduction of inflammatory biomarkers in COVID-19 patients: A meta-analysis.

J Clin Lab Anal · 2022 · PMC9110982 · PMID 35435272

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may not be significantno p-value reported

7 , 10 Although systematic inflammation may not be significant in all patients, there is evidence of localized hyper‐inflammation in the lungs, making Anakinra an attractive candidate for moderate‐to‐severe COVID‐19 infections as concomitant therapy. 7 , 11 , 12 , 13 So far, Anakinra has been administered as an off‐label medication for patien

also in 2,774 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.